Publicações
2017
Kundro MA, Viloria GA, Toibaro JJ, Losso MH. Antiretroviral therapy and arterial elasticity in HIV-infected patients. Medicina (B Aires). 2017;77(5):365-369. PubMed PMID: 29044011.
Stankievich E, Malanca A, Foradori I, Ivalo S, Losso M. Utility of Mobile Communication Devices as a Tool to Improve Adherence to Antiretroviral Treatment in HIV-Infected Children and Young Adults in Argentina. Pediatr Infect Dis J. 2017 Oct 7.
Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med. 2017 Oct 6.
Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017 Dec;17(12):1255-1265.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Med. 2018 Jan;19(1):65-71. Epub 2017 Jul 13.
Currier JS, Britto P, Hoffman RM, Brummel S, Masheto G, Joao E, Santos B, Aurpibul L, Losso M, Pierre MF, Weinberg A, Gnanashanmugam D, Chakhtoura N, Klingman K, Browning R, Coletti A, Mofenson L, Shapiro D, Pilotto J; 1077HS PROMISE Team. Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3. PLoS One. 2017 May
Malanca A, Foradori I, Stankievich E, Pandullo H, Losso M. [Disclosure of human immunodeficiency virus diagnosis in children and adolescents affected by it and their caregivers]. Arch Argent Pediatr. 2017 Apr 1;115(2):195-199.
TB:HIV Study writing Group. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. AIDS. 2017 Jan 28;31(3):375-384.
Pett SL, Kunisaki KM, Wenworth D, y col. Increased indoleamine 2-3 Dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study. Open Forum Infect Dis 2017; Oct 25, 5(1)
Dwyer DE, Lynfield R, Losso MH, y col. Comparison of the outcomes of individuals with medically attended influenza A and B virus infections enrolled in 2 international cohort studies over a 6 year period: 2009-2015. Open Forum Infect Dis 2017; Oct 7;4(4)
Vazquez C, Orlova M, Angriman F, Minatta JN, Scibona P, Verzura MA, Jáuregui EG, Díaz de Arce H, Pallotta MG, Belloso WH. Prediction of severe toxicity in adult patients under treatment with 5-fluoruracil: a prospective cohort study. Anticancer Drugs 2017; Oct 28(9):1039-46.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso WH, Tu E, Silk D, Kelleher A, y col. Week 96 results of the randomized multicentre Maraviroc Switch (MARCH) study. HIV Med 2017; Jul 13
Achhra AC, Mocroft A, Ross M, Ryom-Nyelson L, Avihingsanon A, Bakowska E, Belloso WH, Clarke A, Furrer H, Lucas GM, Ristola M, Rassool M, Ross J, y col. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START Trial. Int J Antimicrob Agents 2017; Jun 28
Vazquez C, Orlova M, Scibona P, Diaz Arce H, Pallotta MG, Belloso WH. Prevalence of thymidylate synthase gene 5´untranslated region variants in an Argentinean sample. Gen Mol res 2017; 16(1)
Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 Jan;4(1):e13-e20.
Stankievich E, Malanca A, Foradori I, Ivalo S, Losso M. Utility of Mobile Communication Devices as a Tool to Improve Adherence to Antiretroviral Treatment in HIV-Infected Children and Young Adults in Argentina. Pediatr Infect Dis J. 2017 Oct 7.
Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med. 2017 Oct 6.
Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017 Dec;17(12):1255-1265.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Med. 2018 Jan;19(1):65-71. Epub 2017 Jul 13.
Currier JS, Britto P, Hoffman RM, Brummel S, Masheto G, Joao E, Santos B, Aurpibul L, Losso M, Pierre MF, Weinberg A, Gnanashanmugam D, Chakhtoura N, Klingman K, Browning R, Coletti A, Mofenson L, Shapiro D, Pilotto J; 1077HS PROMISE Team. Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3. PLoS One. 2017 May
Malanca A, Foradori I, Stankievich E, Pandullo H, Losso M. [Disclosure of human immunodeficiency virus diagnosis in children and adolescents affected by it and their caregivers]. Arch Argent Pediatr. 2017 Apr 1;115(2):195-199.
TB:HIV Study writing Group. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. AIDS. 2017 Jan 28;31(3):375-384.
Pett SL, Kunisaki KM, Wenworth D, y col. Increased indoleamine 2-3 Dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study. Open Forum Infect Dis 2017; Oct 25, 5(1)
Dwyer DE, Lynfield R, Losso MH, y col. Comparison of the outcomes of individuals with medically attended influenza A and B virus infections enrolled in 2 international cohort studies over a 6 year period: 2009-2015. Open Forum Infect Dis 2017; Oct 7;4(4)
Vazquez C, Orlova M, Angriman F, Minatta JN, Scibona P, Verzura MA, Jáuregui EG, Díaz de Arce H, Pallotta MG, Belloso WH. Prediction of severe toxicity in adult patients under treatment with 5-fluoruracil: a prospective cohort study. Anticancer Drugs 2017; Oct 28(9):1039-46.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso WH, Tu E, Silk D, Kelleher A, y col. Week 96 results of the randomized multicentre Maraviroc Switch (MARCH) study. HIV Med 2017; Jul 13
Achhra AC, Mocroft A, Ross M, Ryom-Nyelson L, Avihingsanon A, Bakowska E, Belloso WH, Clarke A, Furrer H, Lucas GM, Ristola M, Rassool M, Ross J, y col. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START Trial. Int J Antimicrob Agents 2017; Jun 28
Vazquez C, Orlova M, Scibona P, Diaz Arce H, Pallotta MG, Belloso WH. Prevalence of thymidylate synthase gene 5´untranslated region variants in an Argentinean sample. Gen Mol res 2017; 16(1)
Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 Jan;4(1):e13-e20.
2016
Rodriguez Loria G, Losso MH, Mosqueda L, Viloria G, Alave J, Andrade Villanueva J, David D, Laplumé H, de Paz M, Lupo S, Michaans M, Belloso WH. Establishment of a prospective cohort of adult HIV positive patients in Latin America (LATINA Prospective Cohort).
Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 Jan;4(1):e13-e20. doi:
Musso CG, Belloso WH. Monitoring of kidney function in elderly HIV-positive patients. HIV Med. 2016 Jul 6. doi: 10.1111/hiv.12395.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group.. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clin Infect Dis. 2016 Jul 1;63(1):122-32
Alvarez E, Belloso WH. Boyd MA, Inkaya AC, Hsieh E, Kambugu A, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW, Which patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS 2016 Feb 18. Epub ahead of print.
Musso CG, Belloso WH. Glassock RJ. Water, electrolytes and acid-base alterations in human immunodeficiency virus infected patients. World J Nephrol 2016 Jan 6;5(1):33-42.
Baker JV, Hullsiek KH, Engen NW, Nelson R, Chetchotisakd P, Gerstoft J, JessenH, Losso M, Markowitz N, Munderi P, Papadopoulos A, Shuter J, Rappoport C,Pearson MT, Finley E, Babiker A, Emery S, Duprez D; INSIGHT START ArterialElasticity Substudy Team.. Early Antiretroviral Therapy at High CD4 Counts DoesNot Improve Arterial Elasticity: A Substudy of the Strategic Timing ofAntiRetroviral Treatment (START) Trial. Open Forum Infect Dis. 2016 Oct8;3(4):ofw213.
Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, MitsuraV, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, SzlavikJ, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R;EuroSIDA Study.. Long-term effectiveness of unboosted atazanavir plusabacavir/lamivudine in subjects with virological suppression: A prospectivecohort study. Medicine (Baltimore). 2016 Oct;95(40):e5020.
Kundro MA, Terwel SR, Toibaro JJ, Viloria GA, Losso MH. Late diagnosis of HIV infection in asymptomatic patients. Medicina (B Aires). 2016;76(5):273-278.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, SierraMadero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W,Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, KaiserR, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; MaravirocSwitch (MARCH) Study Group.. Maraviroc, as a Switch Option, in HIV-1-infectedIndividuals With Stable, Well-controlled HIV Replication and R5-tropic Virus onTheir First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor PlusRitonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clin Infect Dis. 2016 Jul 1;63(1):122-32.
Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A,Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E,Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group inEuroCoord.. Tuberculosis-related mortality in people living with HIV in Europeand Latin America: an international cohort study. Lancet HIV. 2016Mar;3(3):e120-31.
Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, Losso MH,Toibaro J, Skrahin A, Miro JM, Caylà JA, Girardi E, Bruyand M, Obel N,Podlekareva DN, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord..Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS One. 2015 Dec30;10(12):e0145380.
Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, OrrellC, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at96 Weeks: Results of the ENCORE1 Study. Clin Pharmacokinet. 2016Jul;55(7):861-73.
Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA; SECOND-LINE Study Group. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 Jan;4(1):e13-e20. doi:
Musso CG, Belloso WH. Monitoring of kidney function in elderly HIV-positive patients. HIV Med. 2016 Jul 6. doi: 10.1111/hiv.12395.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group.. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clin Infect Dis. 2016 Jul 1;63(1):122-32
Alvarez E, Belloso WH. Boyd MA, Inkaya AC, Hsieh E, Kambugu A, Kaminski G, Martinez E, Stellbrink HJ, Walmsley S, Brown TT, Mallon PW, Which patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS 2016 Feb 18. Epub ahead of print.
Musso CG, Belloso WH. Glassock RJ. Water, electrolytes and acid-base alterations in human immunodeficiency virus infected patients. World J Nephrol 2016 Jan 6;5(1):33-42.
Baker JV, Hullsiek KH, Engen NW, Nelson R, Chetchotisakd P, Gerstoft J, JessenH, Losso M, Markowitz N, Munderi P, Papadopoulos A, Shuter J, Rappoport C,Pearson MT, Finley E, Babiker A, Emery S, Duprez D; INSIGHT START ArterialElasticity Substudy Team.. Early Antiretroviral Therapy at High CD4 Counts DoesNot Improve Arterial Elasticity: A Substudy of the Strategic Timing ofAntiRetroviral Treatment (START) Trial. Open Forum Infect Dis. 2016 Oct8;3(4):ofw213.
Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, MitsuraV, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, SzlavikJ, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R;EuroSIDA Study.. Long-term effectiveness of unboosted atazanavir plusabacavir/lamivudine in subjects with virological suppression: A prospectivecohort study. Medicine (Baltimore). 2016 Oct;95(40):e5020.
Kundro MA, Terwel SR, Toibaro JJ, Viloria GA, Losso MH. Late diagnosis of HIV infection in asymptomatic patients. Medicina (B Aires). 2016;76(5):273-278.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, SierraMadero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W,Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, KaiserR, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; MaravirocSwitch (MARCH) Study Group.. Maraviroc, as a Switch Option, in HIV-1-infectedIndividuals With Stable, Well-controlled HIV Replication and R5-tropic Virus onTheir First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor PlusRitonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clin Infect Dis. 2016 Jul 1;63(1):122-32.
Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A,Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E,Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group inEuroCoord.. Tuberculosis-related mortality in people living with HIV in Europeand Latin America: an international cohort study. Lancet HIV. 2016Mar;3(3):e120-31.
Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, Losso MH,Toibaro J, Skrahin A, Miro JM, Caylà JA, Girardi E, Bruyand M, Obel N,Podlekareva DN, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord..Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS One. 2015 Dec30;10(12):e0145380.
Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, OrrellC, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at96 Weeks: Results of the ENCORE1 Study. Clin Pharmacokinet. 2016Jul;55(7):861-73.
2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group. Lancet HIV. 2015 Feb;2(2):e42-51. doi: 10.1016/S2352-3018(14)00061-7
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816.
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156.
INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy. Hullsiek KH, Kagan JM, Engen N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH. Ther Innov Regul Sci. 2015 Mar 1;49(2):225-233.
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. PLoS Med. 2015 Mar 31;12(3):e1001809.
Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study. Angriman F, Belloso WH, Sierra-Madero J, Sánchez J, Moreira RI, Kovalevski LO, Orellana LC, Cardoso SW, Crabtree-Ramirez B, La Rosa A, Losso MH. Int J STD AIDS. 2016 Feb;27(2):118-26.
Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA; ALTAIR Study Group. PLoS One. 2015 Feb 27;10(2):e0118608.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816.
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156.
INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy. Hullsiek KH, Kagan JM, Engen N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH. Ther Innov Regul Sci. 2015 Mar 1;49(2):225-233.
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. PLoS Med. 2015 Mar 31;12(3):e1001809.
Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study. Angriman F, Belloso WH, Sierra-Madero J, Sánchez J, Moreira RI, Kovalevski LO, Orellana LC, Cardoso SW, Crabtree-Ramirez B, La Rosa A, Losso MH. Int J STD AIDS. 2016 Feb;27(2):118-26.
Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA; ALTAIR Study Group. PLoS One. 2015 Feb 27;10(2):e0118608.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227.
2014
Angriman F, Belloso WH, Sierra Madero J, Sanchez J, Moreira RI, Kovalevski LO, Orellana LC, Cardoso SW, Crabtree Ramirez B, La Rosa A, Losso MH. Clinical Outcomes of first line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study. Int J STD AIDS 2015, Mar 3.
Huppler Hulsiek K, Kagan JM, Engen N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH. Investigating the efficacy of clinical trial monitoring strategies: design and implementation of the cluster randomized Start monitoring substudy. Ther Innov Reg Sci, 2014: 1-9
Haskelberg H, Mallon PW, Hoy J, Amin J, Moore C, Phanuphak P, Ferret S, Belloso WH, Boyd MA, Cooper DA, Emery S. Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. J Acquir Immune Defic Syndr. 2014 Jul 25.
Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014 May 28;3(3):e000844.
Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One. 2014 Mar 13;9(3):e90978.
ENCORE1 Study Group, Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, Young B, Shahar E, Wolff M, Gazzard B, Read T, Hill A, Cooper DA, Emery S Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014 Apr 26;383(9927):1474-82
Huppler Hulsiek K, Kagan JM, Engen N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH. Investigating the efficacy of clinical trial monitoring strategies: design and implementation of the cluster randomized Start monitoring substudy. Ther Innov Reg Sci, 2014: 1-9
Haskelberg H, Mallon PW, Hoy J, Amin J, Moore C, Phanuphak P, Ferret S, Belloso WH, Boyd MA, Cooper DA, Emery S. Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. J Acquir Immune Defic Syndr. 2014 Jul 25.
Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014 May 28;3(3):e000844.
Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One. 2014 Mar 13;9(3):e90978.
ENCORE1 Study Group, Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, Young B, Shahar E, Wolff M, Gazzard B, Read T, Hill A, Cooper DA, Emery S Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014 Apr 26;383(9927):1474-82
2013
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Lancet. 2013 Jun 15;381(9883):2091-9.
Short and long term mortality and causes of death in HIV/TB patients in Europe.
Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; the HIV/TB study group. Eur Respir J. 2013 Jun 13.
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD. AIDS. 2013 Mar 27;27(6):907-18.
Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus.Saira K, Lin X, DePasse JV, Halpin R, Twaddle A, Stockwell T, Angus B, Cozzi-Lepri A, Delfino M, Dugan V, Dwyer DE, Freiberg M, Horban A, Losso M, Lynfield R, Wentworth DN, Holmes EC, Davey R, Wentworth DE, Ghedin E; INSIGHT FLU002 Study Group; INSIGHT FLU003 Study Group. J Virol. 2013 Jul;87(14):8064-74.
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group. J Clin Microbiol. 2013 Jul;51(7):2063-71.
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte Ad, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A; EuroSIDA in EuroCoord. J Hepatol. 2013 Aug;59(2):213-20.
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research). HIV Med. 2013 Jul;14(6):370-8.
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Clin Infect Dis. 2013 Jul;57(1):112-21.
The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. PLoS One. 2013;8(2):e57121.
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group. PLoS One. 2013;8(2):e56249.
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. J Infect Dis. 2013 May 1;207(9):1359-69.
Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group.
Int J Tuberc Lung Dis. 2013 Feb;17(2):198-206.
Platelet count kinetics following interruption of antiretroviral treatment.Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. AIDS. 2013 Jan 2;27(1):59-68.
Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso WH y col. HIV lipodystrophy in participants randomised to Lopinavir/ritonavir (LPV/r) +2-3 Nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line antiretroviral therapy. PloS One 2013; 8(10):e77138.
Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso W y col. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard Second Line therapy. AIDS 2013, Aug 6 [epub ahead of print]
SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013 Jun 15;381(9883):2091-9.
Bierk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group. Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PloS One 2013;8(2):e56249.
Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. Platelet count kinetics following interruption of antiretroviral treatment. AIDS 2013 Juan 2;27(1):59-68.
Short and long term mortality and causes of death in HIV/TB patients in Europe.
Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; the HIV/TB study group. Eur Respir J. 2013 Jun 13.
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD. AIDS. 2013 Mar 27;27(6):907-18.
Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus.Saira K, Lin X, DePasse JV, Halpin R, Twaddle A, Stockwell T, Angus B, Cozzi-Lepri A, Delfino M, Dugan V, Dwyer DE, Freiberg M, Horban A, Losso M, Lynfield R, Wentworth DN, Holmes EC, Davey R, Wentworth DE, Ghedin E; INSIGHT FLU002 Study Group; INSIGHT FLU003 Study Group. J Virol. 2013 Jul;87(14):8064-74.
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group. J Clin Microbiol. 2013 Jul;51(7):2063-71.
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte Ad, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A; EuroSIDA in EuroCoord. J Hepatol. 2013 Aug;59(2):213-20.
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research). HIV Med. 2013 Jul;14(6):370-8.
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Clin Infect Dis. 2013 Jul;57(1):112-21.
The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups. PLoS One. 2013;8(2):e57121.
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group. PLoS One. 2013;8(2):e56249.
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. J Infect Dis. 2013 May 1;207(9):1359-69.
Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group.
Int J Tuberc Lung Dis. 2013 Feb;17(2):198-206.
Platelet count kinetics following interruption of antiretroviral treatment.Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. AIDS. 2013 Jan 2;27(1):59-68.
Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso WH y col. HIV lipodystrophy in participants randomised to Lopinavir/ritonavir (LPV/r) +2-3 Nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line antiretroviral therapy. PloS One 2013; 8(10):e77138.
Martin A, Moore C, Mallon PW, Hoy J, Emery S, Belloso W y col. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard Second Line therapy. AIDS 2013, Aug 6 [epub ahead of print]
SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013 Jun 15;381(9883):2091-9.
Bierk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group. Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PloS One 2013;8(2):e56249.
Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group. Platelet count kinetics following interruption of antiretroviral treatment. AIDS 2013 Juan 2;27(1):59-68.
2012
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol. 2012 Dec;41(6):1807-20.
Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J; STALWART Study Group. PLoS One. 2012;7(10):e47506.
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. J Int AIDS Soc. 2012 Oct 10;15(2):17426.
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD. Antivir Ther. 2012;17(7):1291-300.
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O; EuroSIDA study in EuroCoord. BMC Infect Dis. 2012 Sep 25;12:229.
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. PLoS One. 2012;7(7):e41673
Missed opportunities for prevention of mother-to-child transmission of HIV-1 in the NISDI Perinatal and LILAC cohorts.Read JS, Cohen RA, Hance LF, Machado ES, Mussi-Pinhata MM, Ceriotto M, Santos B, Succi R, Pilotto JH, Alarcon JO, Kreitchmann R; NISDI Perinatal/LILAC Study Group. Int J Gynaecol Obstet. 2012 Oct;119(1):70-5. Epub 2012 Jul 21.
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord. AIDS. 2012 Sep 24;26(15):1917-26.
Antiretroviral adherence during pregnancy and postpartum in Latin America.Kreitchmann R, Harris DR, Kakehasi F, Haberer JE, Cahn P, Losso M, Teles E, Pilotto JH, Hofer CB, Read JS; NISDI LILAC Study Team. AIDS Patient Care STDS. 2012 Aug;26(8):486-95.
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group. AIDS. 2012 Jan 28;26(3):315-23.
The NICHD International Site Development Initiative perinatal cohorts (2002-09). Read JS, Duarte G, Hance LF, Pinto J, Gouvea MI, Cohen RA, Santos B, Teles E, Succi R, Alarcon J, Stoszek SK; NISDI Perinatal Study Group. Int J Epidemiol. 2012 Jun;41(3):642-9.
Duprez, DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD; INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e44454. doi: 10.1371/journal.pone.0044454. Epub 2012 Sep 10.
Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.Markowitz N, Lopardo G, Wentworth D, Gey D, Babiker A, Fox L, Tavel J; STALWART Study Group. PLoS One. 2012;7(10):e47506.
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. J Int AIDS Soc. 2012 Oct 10;15(2):17426.
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD. Antivir Ther. 2012;17(7):1291-300.
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O; EuroSIDA study in EuroCoord. BMC Infect Dis. 2012 Sep 25;12:229.
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. PLoS One. 2012;7(7):e41673
Missed opportunities for prevention of mother-to-child transmission of HIV-1 in the NISDI Perinatal and LILAC cohorts.Read JS, Cohen RA, Hance LF, Machado ES, Mussi-Pinhata MM, Ceriotto M, Santos B, Succi R, Pilotto JH, Alarcon JO, Kreitchmann R; NISDI Perinatal/LILAC Study Group. Int J Gynaecol Obstet. 2012 Oct;119(1):70-5. Epub 2012 Jul 21.
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord. AIDS. 2012 Sep 24;26(15):1917-26.
Antiretroviral adherence during pregnancy and postpartum in Latin America.Kreitchmann R, Harris DR, Kakehasi F, Haberer JE, Cahn P, Losso M, Teles E, Pilotto JH, Hofer CB, Read JS; NISDI LILAC Study Team. AIDS Patient Care STDS. 2012 Aug;26(8):486-95.
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group. AIDS. 2012 Jan 28;26(3):315-23.
The NICHD International Site Development Initiative perinatal cohorts (2002-09). Read JS, Duarte G, Hance LF, Pinto J, Gouvea MI, Cohen RA, Santos B, Teles E, Succi R, Alarcon J, Stoszek SK; NISDI Perinatal Study Group. Int J Epidemiol. 2012 Jun;41(3):642-9.
Duprez, DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD; INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e44454. doi: 10.1371/journal.pone.0044454. Epub 2012 Sep 10.
2011
Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A; EuroSIDA in EuroCoord. AIDS. 2011 Nov 28;25(18):2259-68.
Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.Dwyer DE; INSIGHT Influenza Study Group. Vaccine. 2011 Jul 22;29 Suppl 2:B56-62.
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. AIDS. 2011 Jul 31;25(12):1505-13.
Mode of delivery and neonatal respiratory morbidity among HIV-exposed newborns in Latin America and the Caribbean: NISDI Perinatal-LILAC Studies.Kreitchmann R, Cohen RA, Stoszek SK, Pinto JA, Losso M, Pierre R, Alarcon J, Succi R, Szyld E, Abreu T, Read JS. Int J Gynaecol Obstet. 2011 Aug;114(2):91-6.
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group. AIDS. 2011 Jun 19;25(10):1305-15.
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; Eurosida Study Group. HIV Clin Trials. 2011 Mar-Apr;12(2):109-17.
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. J Antimicrob Chemother. 2011 Apr;66(4):901-11.
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group. HIV Med. 2011 May;12(5):259-68.
Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD; INSIGHT SMART Study Group. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):36-43.
Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.Dwyer DE; INSIGHT Influenza Study Group. Vaccine. 2011 Jul 22;29 Suppl 2:B56-62.
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. AIDS. 2011 Jul 31;25(12):1505-13.
Mode of delivery and neonatal respiratory morbidity among HIV-exposed newborns in Latin America and the Caribbean: NISDI Perinatal-LILAC Studies.Kreitchmann R, Cohen RA, Stoszek SK, Pinto JA, Losso M, Pierre R, Alarcon J, Succi R, Szyld E, Abreu T, Read JS. Int J Gynaecol Obstet. 2011 Aug;114(2):91-6.
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group. AIDS. 2011 Jun 19;25(10):1305-15.
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; Eurosida Study Group. HIV Clin Trials. 2011 Mar-Apr;12(2):109-17.
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. J Antimicrob Chemother. 2011 Apr;66(4):901-11.
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group. HIV Med. 2011 May;12(5):259-68.
Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD; INSIGHT SMART Study Group. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):36-43.
2010
Dialysis and renal transplantation in HIV-infected patients: a European survey.Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miró JM; EuroSIDA Investigators. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):582-9.
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group. J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70.
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group. Cancer. 2010 Nov 15;116(22):5306-15.
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA; INSIGHT ESPRIT & SILCAAT study groups. AIDS. 2010 Jul 31;24(12):1877-86.
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. AIDS. 2010 Jul 17;24(11):1667-78.
Lower respiratory tract infections among human immunodeficiency virus-exposed, uninfected infants.Mussi-Pinhata MM, Motta F, Freimanis-Hance L, de Souza R, Szyld E, Succi RC, Christie CD, Rolon MJ, Ceriotto M, Read JS; NISDI Perinatal Study Group. Int J Infect Dis. 2010 Sep;14 Suppl 3:e176-82.
Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites.Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, Sanchez J, Ismerio Moreira R, Crabtree-Ramirez B, Garcia Messina O, Lasala MB, Peinado J, Losso MH.
HIV Med. 2010 Oct 1;11(9):554-64.
Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, Ivalo SA, Pierre R, Reyes M, Heather Watts D, Read JS; NISDI Perinatal Study Group. J Acquir Immune Defic Syndr. 2010 Feb;53(2):176-85.
Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J; EuroSIDA. J Antimicrob Chemother. 2010 Mar;65(3):548-55.
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. AIDS. 2010 Jan 28;24(3):427-35.
Lifson AR, INSIGHT Endpoint Review Committee Writing Group, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J, INSIGHT Study Group. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials. 2010 Jul-Aug;11(4):205-19.
Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group. E, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010 Oct 1;51(7):855-64
Belloso WH, Redal MA. Pharmacogenomics and the path towards personalized medicine. Medicina (Buenos Aires), 2010; 70(3):265-74
Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, Sanchez J, Ismerio Moreira R, Crabtree-Ramirez B, Garcia Messina O, Lasala MB, Peinado J, Losso MH. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites HIV Med. 2010 Mar 21. [Epub ahead of print]
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group. J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70.
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group. Cancer. 2010 Nov 15;116(22):5306-15.
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA; INSIGHT ESPRIT & SILCAAT study groups. AIDS. 2010 Jul 31;24(12):1877-86.
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. AIDS. 2010 Jul 17;24(11):1667-78.
Lower respiratory tract infections among human immunodeficiency virus-exposed, uninfected infants.Mussi-Pinhata MM, Motta F, Freimanis-Hance L, de Souza R, Szyld E, Succi RC, Christie CD, Rolon MJ, Ceriotto M, Read JS; NISDI Perinatal Study Group. Int J Infect Dis. 2010 Sep;14 Suppl 3:e176-82.
Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites.Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, Sanchez J, Ismerio Moreira R, Crabtree-Ramirez B, Garcia Messina O, Lasala MB, Peinado J, Losso MH.
HIV Med. 2010 Oct 1;11(9):554-64.
Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, Ivalo SA, Pierre R, Reyes M, Heather Watts D, Read JS; NISDI Perinatal Study Group. J Acquir Immune Defic Syndr. 2010 Feb;53(2):176-85.
Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J; EuroSIDA. J Antimicrob Chemother. 2010 Mar;65(3):548-55.
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. AIDS. 2010 Jan 28;24(3):427-35.
Lifson AR, INSIGHT Endpoint Review Committee Writing Group, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J, INSIGHT Study Group. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials. 2010 Jul-Aug;11(4):205-19.
Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group. E, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010 Oct 1;51(7):855-64
Belloso WH, Redal MA. Pharmacogenomics and the path towards personalized medicine. Medicina (Buenos Aires), 2010; 70(3):265-74
Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, Sanchez J, Ismerio Moreira R, Crabtree-Ramirez B, Garcia Messina O, Lasala MB, Peinado J, Losso MH. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites HIV Med. 2010 Mar 21. [Epub ahead of print]
2009
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group.
AIDS. 2009 Nov 27;23(18):2485-95.
Benefits and burdens of participation in a longitudinal clinical trial.Lazovski J, Losso M, Krohmal B, Emanuel EJ, Grady C, Wendler D. J Empir Res Hum Res Ethics. 2009 Sep;4(3):89-97.
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. J Infect Dis. 2009 Sep 15;200(6):973-83.
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group. J Infect Dis. 2009 Sep 1;200(5):687-97.
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group.
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):457-63.
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis. 2009 Apr 15;48(8):1138-51.
Interruption of antiretroviral therapy is associated with increased plasma cystatin C.Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group. AIDS. 2009 Jan 2;23(1):71-82.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15;361(16):1548-59
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009 Sep 15;200(6):973-83.
AIDS. 2009 Nov 27;23(18):2485-95.
Benefits and burdens of participation in a longitudinal clinical trial.Lazovski J, Losso M, Krohmal B, Emanuel EJ, Grady C, Wendler D. J Empir Res Hum Res Ethics. 2009 Sep;4(3):89-97.
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. J Infect Dis. 2009 Sep 15;200(6):973-83.
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group. J Infect Dis. 2009 Sep 1;200(5):687-97.
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group.
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):457-63.
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis. 2009 Apr 15;48(8):1138-51.
Interruption of antiretroviral therapy is associated with increased plasma cystatin C.Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group. AIDS. 2009 Jan 2;23(1):71-82.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15;361(16):1548-59
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009 Sep 15;200(6):973-83.
2008
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. AIDS. 2008 Nov 30;22(18):2481-92.
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group. AIDS. 2008 Nov 12;22(17):2381-90.
The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results.Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. Cent Eur J Public Health. 2008 Sep;16(3):99-105. Review.
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe.Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. J Infect Dis. 2008 Nov 1;198(9):1337-44.
Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD; Eurosida Study Group. Scand J Infect Dis. 2008;40(11-12):908-13.
Determination of the underlying cause of death in three multicenter international HIV clinical trials.Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.
HIV Clin Trials. 2008 May-Jun;9(3):177-85.
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33.
Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs.Soto-Ramirez LE, Rodriguez-Diaz R, Durán AS, Losso MH, Salomón H, Gómez-Carrillo M, Pampuro S, Harris DR, Duarte G, De Souza RS, Read JS; NISDI Perinatal Study Group. AIDS Res Hum Retroviruses. 2008 Jun;24(6):797-804.
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. J Infect Dis. 2008 Apr 15;197(8):1145-55.
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. J Infect Dis. 2008 Apr 15;197(8):1133-44.
Loss to follow-up in an international, multicentre observational study.Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group. HIV Med. 2008 May;9(5):261-9.
Laboratory abnormalities among HIV-1-infected pregnant women receiving antiretrovirals in Latin America and the Caribbean.Ceriotto M, Harris DR, Duarte G, Gonin R, Aguiar RP, Warley EM, Madi JM, Zala CA, Read JS; NICHD International Site Development Initiative (NISDI) Perinatal Study Group. AIDS Patient Care STDS. 2008 Mar;22(3):167-71. No abstract available.
Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008 Nov 12;22(17):2279-89.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21;5(10):e203.
SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008 Sep 2;149(5):289-99
Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials. 2008 May-Jun;9(3):177-85.
Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13(2):177-87.
SMART CVD Working Group: Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman W, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: findings from the SMART trial. Antiviral Therapy 2008 (in press).
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group. AIDS. 2008 Nov 12;22(17):2381-90.
The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results.Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. Cent Eur J Public Health. 2008 Sep;16(3):99-105. Review.
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe.Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. J Infect Dis. 2008 Nov 1;198(9):1337-44.
Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD; Eurosida Study Group. Scand J Infect Dis. 2008;40(11-12):908-13.
Determination of the underlying cause of death in three multicenter international HIV clinical trials.Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.
HIV Clin Trials. 2008 May-Jun;9(3):177-85.
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33.
Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs.Soto-Ramirez LE, Rodriguez-Diaz R, Durán AS, Losso MH, Salomón H, Gómez-Carrillo M, Pampuro S, Harris DR, Duarte G, De Souza RS, Read JS; NISDI Perinatal Study Group. AIDS Res Hum Retroviruses. 2008 Jun;24(6):797-804.
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. J Infect Dis. 2008 Apr 15;197(8):1145-55.
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. J Infect Dis. 2008 Apr 15;197(8):1133-44.
Loss to follow-up in an international, multicentre observational study.Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group. HIV Med. 2008 May;9(5):261-9.
Laboratory abnormalities among HIV-1-infected pregnant women receiving antiretrovirals in Latin America and the Caribbean.Ceriotto M, Harris DR, Duarte G, Gonin R, Aguiar RP, Warley EM, Madi JM, Zala CA, Read JS; NICHD International Site Development Initiative (NISDI) Perinatal Study Group. AIDS Patient Care STDS. 2008 Mar;22(3):167-71. No abstract available.
Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008 Nov 12;22(17):2279-89.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21;5(10):e203.
SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008 Sep 2;149(5):289-99
Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials. 2008 May-Jun;9(3):177-85.
Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13(2):177-87.
SMART CVD Working Group: Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman W, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: findings from the SMART trial. Antiviral Therapy 2008 (in press).
2007
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.ESPRIT Research Group, Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD. HIV Med. 2007 Mar;8(2):112-23.
Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study.Mussi-Pinhata MM, Freimanis L, Yamamoto AY, Korelitz J, Pinto JA, Cruz ML, Losso MH, Read JS; National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study Group. Pediatrics. 2007 Mar;119(3):e694-704. Epub 2007 Feb 12.
When should antiretroviral therapy for HIV be started?Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. BMJ. 2007 Jan 13;334(7584):76-8. Review. No abstract available.
Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries.Gomez-Carrillo M, Pampuro S, Duran A, Losso M, Harris DR, Read JS, Duarte G, De Souza R, Soto-Ramirez L, Salomón H; NISDI Perinatal Study Group. AIDS Res Hum Retroviruses. 2006 Nov;22(11):1186-91.
Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.Duran AS, Losso MH, Salomón H, Harris DR, Pampuro S, Soto-Ramirez LE, Duarte G, de Souza RS, Read JS; NISDI Perinatal Study Group. AIDS. 2007 Jan 11;21(2):199-205.
Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study.Mussi-Pinhata MM, Freimanis L, Yamamoto AY, Korelitz J, Pinto JA, Cruz ML, Losso MH, Read JS; National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study Group. Pediatrics. 2007 Mar;119(3):e694-704. Epub 2007 Feb 12.
When should antiretroviral therapy for HIV be started?Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. BMJ. 2007 Jan 13;334(7584):76-8. Review. No abstract available.
Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries.Gomez-Carrillo M, Pampuro S, Duran A, Losso M, Harris DR, Read JS, Duarte G, De Souza R, Soto-Ramirez L, Salomón H; NISDI Perinatal Study Group. AIDS Res Hum Retroviruses. 2006 Nov;22(11):1186-91.
Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.Duran AS, Losso MH, Salomón H, Harris DR, Pampuro S, Soto-Ramirez LE, Duarte G, de Souza RS, Read JS; NISDI Perinatal Study Group. AIDS. 2007 Jan 11;21(2):199-205.
2006
Prevention of mother to child HIV transmission.Duran AS, Ivalo SA, Hakim A, Masciottra FM, Zlatkes R, Adissi L, Neaton JD, Losso MH. Medicina (B Aires). 2006;66(1):24-30.
Lifson AR, Rhame FS, Belloso WH, Dragsted UB, El-Sadr WM, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Pett SL, Davey RT Jr. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clinical Trials 2006 May-Jun; 7(3): 125-41.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 Nov 30;355(22):2283-96.
Lifson AR, Rhame FS, Belloso WH, Dragsted UB, El-Sadr WM, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Pett SL, Davey RT Jr. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clinical Trials 2006 May-Jun; 7(3): 125-41.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 Nov 30;355(22):2283-96.
2005
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J; EuroSIDA Study Group. J Infect Dis. 2005 Sep 15;192(6):992-1002. Epub 2005 Aug 11.
2004
CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende MC, Emery S, Fosdick L, Neaton J, Tavel JA, Davey RT, Lane HC; Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) Vanguard Group; ESPRIT Executive Committee. Clin Infect Dis. 2004 Jul 1;39(1):115-22. Epub 2004 Jun 14.
2000
Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, Lopardo G, Salomon H, Saracco M, Nelson E, Law MG, Davey RT, Allende MC, Lane HC. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. J Infect Dis 2000 May, 181(5): 1614-21.